Biotech: Disrupted.

As the number of Covid-19 cases expand globally, every corner of the biotech industry will be impacted in some way. There will be office interruptions, delays in drug development and clinical trials, extensions of regulatory reviews, and limits on new drug launches. Sales of certain older drugs will drop along with prescriptions. Expect investor and financing challenges, too.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Adam,

    Why worry about Italy? So what if all the clincal trails in that country girnds to a halt? I am sure you know as well as I do that among the Big 5 EU nations as a drug market (UK, Germany, France, Spain and Italy), Italy with only barely 60 million people is a small fraction with insignificant revenue for any new drug and also for any existing drug sold in that country. So what if any new drug is NOT approved in Italy. Big deal. Patients in dire needs can always drive across the border to get it!

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy